{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T02:48:19Z","timestamp":1790131699048,"version":"4.0.1"},"reference-count":82,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T00:00:00Z","timestamp":1769990400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100011033","name":"State Agency of Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011033","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014440","name":"Spain Ministry of Science Innovation and Universities","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014440","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003359","name":"Generalitat of Valencia","doi-asserted-by":"publisher","award":["CIPROM\/2023\/22"],"award-info":[{"award-number":["CIPROM\/2023\/22"]}],"id":[{"id":"10.13039\/501100003359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003359","name":"Generalitat of Valencia","doi-asserted-by":"publisher","award":["PROMETEO\/2020\/081"],"award-info":[{"award-number":["PROMETEO\/2020\/081"]}],"id":[{"id":"10.13039\/501100003359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003359","name":"Generalitat of Valencia","doi-asserted-by":"publisher","award":["FDEGENT\/2020\/011"],"award-info":[{"award-number":["FDEGENT\/2020\/011"]}],"id":[{"id":"10.13039\/501100003359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010434","name":"Caixabank SA","doi-asserted-by":"publisher","award":["HR17-00268"],"award-info":[{"award-number":["HR17-00268"]}],"id":[{"id":"10.13039\/100010434","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Carlos III Health Institute","doi-asserted-by":"publisher","award":["DTS19\/0128"],"award-info":[{"award-number":["DTS19\/0128"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Human Genetics"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.ajhg.2026.01.016","type":"journal-article","created":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T15:45:16Z","timestamp":1771602316000},"page":"529-547","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Enhanced muscle uptake of chemically optimized miR-23b antisense oligonucleotides as lead compounds for myotonic dystrophy type 1"],"prefix":"10.1016","volume":"113","author":[{"given":"Irene","family":"Gonz\u00e1lez-Mart\u00ednez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Estefan\u00eda","family":"Cerro-Herreros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Carrascosa-S\u00e0ez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Garc\u00eda-Rey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"Piqueras-Losilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Colom-Rodrigo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nerea","family":"Moreno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mouli","family":"Chakraborty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aline","family":"Huguet-Lachon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anchel","family":"Gonz\u00e1lez-Barriga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neia","family":"Naldaiz-Gastesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martxel","family":"Dehesa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"D\u00edaz-Maqueda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuria","family":"Barquero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel A.","family":"Varela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adolfo","family":"L\u00f3pez de Munain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramon","family":"Eritja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Genevi\u00e8ve","family":"Gourdon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arturo","family":"L\u00f3pez-Castel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"P\u00e9rez-Alonso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz","family":"Llamusi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rub\u00e9n","family":"Artero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ajhg.2026.01.016_bib1","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1212\/CPJ.0000000000000531","article-title":"Consensus-based care recommendations for adults with myotonic dystrophy type 1","volume":"8","author":"Ashizawa","year":"2018","journal-title":"Neurol. Clin. Pract."},{"key":"10.1016\/j.ajhg.2026.01.016_bib2","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1111\/brv.12674","article-title":"The hallmarks of myotonic dystrophy type 1 muscle dysfunction","volume":"96","author":"Ozimski","year":"2021","journal-title":"Biol. Rev. Camb. Phil. Soc."},{"key":"10.1016\/j.ajhg.2026.01.016_bib3","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1111\/j.1365-2443.2007.01112.x","article-title":"Defective mRNA in myotonic dystrophy accumulates at the periphery of nuclear splicing speckles","volume":"12","author":"Holt","year":"2007","journal-title":"Genes Cells"},{"key":"10.1016\/j.ajhg.2026.01.016_bib4","doi-asserted-by":"crossref","first-page":"2467","DOI":"10.1093\/nar\/gkp1209","article-title":"MBNL1 binds GC motifs embedded in pyrimidines to regulate alternative splicing","volume":"38","author":"Goers","year":"2010","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ajhg.2026.01.016_bib5","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.molcel.2014.08.027","article-title":"Loss of MBNL leads to disruption of developmentally regulated alternative polyadenylation in RNA-mediated disease","volume":"56","author":"Batra","year":"2014","journal-title":"Mol. Cell"},{"key":"10.1016\/j.ajhg.2026.01.016_bib6","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1093\/hmg\/ddl132","article-title":"Failure of MBNL1-dependent post-natal splicing transitions in myotonic dystrophy","volume":"15","author":"Lin","year":"2006","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.ajhg.2026.01.016_bib7","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.molcel.2007.07.027","article-title":"Increased steady-state levels of CUGBP1 in myotonic dystrophy 1 are due to PKC-mediated hyperphosphorylation","volume":"28","author":"Kuyumcu-Martinez","year":"2007","journal-title":"Mol. Cell"},{"key":"10.1016\/j.ajhg.2026.01.016_bib8","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1101\/gr.184390.114","article-title":"Antagonistic regulation of mRNA expression and splicing by CELF and MBNL proteins","volume":"25","author":"Wang","year":"2015","journal-title":"Genome Res."},{"key":"10.1016\/j.ajhg.2026.01.016_bib9","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms11067","article-title":"Splicing misregulation of SCN5A contributes to cardiac-conduction delay and heart arrhythmia in myotonic dystrophy","volume":"7","author":"Freyermuth","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ajhg.2026.01.016_bib10","first-page":"3952","article-title":"Correction of ClC-1 splicing eliminates chloride channelopathy and myotonia in mouse models of myotonic dystrophy","volume":"117","author":"Wheeler","year":"2007","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.ajhg.2026.01.016_bib11","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/ng704","article-title":"Aberrant regulation of insulin receptor alternative splicing is associated with insulin resistance in myotonic dystrophy","volume":"29","author":"Savkur","year":"2001","journal-title":"Nat. Genet."},{"key":"10.1016\/j.ajhg.2026.01.016_bib12","doi-asserted-by":"crossref","DOI":"10.1172\/JCI173576","article-title":"Verapamil mitigates chloride and calcium bi-channelopathy in a myotonic dystrophy mouse model","volume":"134","author":"Cisco","year":"2024","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.ajhg.2026.01.016_bib13","doi-asserted-by":"crossref","first-page":"519","DOI":"10.3389\/fneur.2018.00519","article-title":"Of Mice and Men: Advances in the Understanding of Neuromuscular Aspects of Myotonic Dystrophy","volume":"9","author":"Braz","year":"2018","journal-title":"Front. Neurol."},{"key":"10.1016\/j.ajhg.2026.01.016_bib14","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1002\/j.2040-4603.2018.tb00015.x","article-title":"Myotonic Dystrophy and Developmental Regulation of RNA Processing","volume":"8","author":"Thomas","year":"2018","journal-title":"Compr. Physiol."},{"key":"10.1016\/j.ajhg.2026.01.016_bib15","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0217317","article-title":"(CTG)n repeat-mediated dysregulation of MBNL1 and MBNL2 expression during myogenesis in DM1 occurs already at the myoblast stage","volume":"14","author":"Andr\u00e9","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.ajhg.2026.01.016_bib16","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1113\/JP277123","article-title":"Chronic exercise mitigates disease mechanisms and improves muscle function in myotonic dystrophy type 1 mice","volume":"597","author":"Manta","year":"2019","journal-title":"J. Physiol."},{"key":"10.1016\/j.ajhg.2026.01.016_bib17","doi-asserted-by":"crossref","first-page":"4645","DOI":"10.1093\/hmg\/dds306","article-title":"Mouse model of muscleblind-like 1 overexpression: skeletal muscle effects and therapeutic promise","volume":"21","author":"Chamberlain","year":"2012","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.ajhg.2026.01.016_bib18","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1016\/j.ebiom.2015.07.028","article-title":"Muscleblind-Like 1 and Muscleblind-Like 3 Depletion Synergistically Enhances Myotonia by Altering Clc-1 RNA Translation","volume":"2","author":"Choi","year":"2015","journal-title":"EBioMedicine"},{"key":"10.1016\/j.ajhg.2026.01.016_bib19","doi-asserted-by":"crossref","first-page":"75","DOI":"10.3389\/fnana.2019.00075","article-title":"Deprivation of Muscleblind-Like Proteins Causes Deficits in Cortical Neuron Distribution and Morphological Changes in Dendritic Spines and Postsynaptic Densities","volume":"13","author":"Lee","year":"2019","journal-title":"Front. Neuroanat."},{"key":"10.1016\/j.ajhg.2026.01.016_bib20","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/j.cell.2012.06.041","article-title":"Transcriptome-wide regulation of pre-mRNA splicing and mRNA localization by muscleblind proteins","volume":"150","author":"Wang","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.ajhg.2026.01.016_bib21","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1038\/s41467-018-04370-x","article-title":"rbFOX1\/MBNL1 competition for CCUG RNA repeats binding contributes to myotonic dystrophy type 1\/type 2 differences","volume":"9","author":"Sellier","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ajhg.2026.01.016_bib22","doi-asserted-by":"crossref","first-page":"11748","DOI":"10.1073\/pnas.0604970103","article-title":"Reversal of RNA missplicing and myotonia after muscleblind overexpression in a mouse poly(CUG) model for myotonic dystrophy","volume":"103","author":"Kanadia","year":"2006","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ajhg.2026.01.016_bib23","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0072907","article-title":"Age of Onset of RNA Toxicity Influences Phenotypic Severity: Evidence from an Inducible Mouse Model of Myotonic Dystrophy (DM1)","volume":"8","author":"Gladman","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.ajhg.2026.01.016_bib24","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1038\/s41467-018-04892-4","article-title":"miR-23b and miR-218 silencing increase Muscleblind-like expression and alleviate myotonic dystrophy phenotypes in mammalian models","volume":"9","author":"Cerro-Herreros","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ajhg.2026.01.016_bib25","doi-asserted-by":"crossref","first-page":"12055","DOI":"10.1093\/nar\/gkae774","article-title":"MBNL splicing factors regulate the microtranscriptome of skeletal muscles","volume":"52","author":"Piasecka","year":"2024","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ajhg.2026.01.016_bib26","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.omtn.2021.07.017","article-title":"Preclinical characterization of antagomiR-218 as a potential treatment for myotonic dystrophy","volume":"26","author":"Cerro-Herreros","year":"2021","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.ajhg.2026.01.016_bib27","doi-asserted-by":"crossref","first-page":"eadn6525","DOI":"10.1126\/sciadv.adn6525","article-title":"AntimiR treatment corrects myotonic dystrophy primary cell defects across several CTG repeat expansions with a dual mechanism of action","volume":"10","author":"Cerro-Herreros","year":"2024","journal-title":"Sci. Adv."},{"key":"10.1016\/j.ajhg.2026.01.016_bib28","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/0092-8674(92)90154-5","article-title":"Molecular basis of myotonic dystrophy: expansion of a trinucleotide (CTG) repeat at the 3\u2019 end of a transcript encoding a protein kinase family member","volume":"68","author":"Brook","year":"1992","journal-title":"Cell"},{"key":"10.1016\/j.ajhg.2026.01.016_bib29","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/391821","article-title":"Molecular genetics and genetic testing in myotonic dystrophy type 1","volume":"2013","author":"Savi\u0107 Pavi\u0107evi\u0107","year":"2013","journal-title":"BioMed Res. Int."},{"key":"10.1016\/j.ajhg.2026.01.016_bib30","doi-asserted-by":"crossref","DOI":"10.3390\/ijms222111874","article-title":"Cardiac Pathology in Myotonic Dystrophy Type 1","volume":"22","author":"Mahadevan","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ajhg.2026.01.016_bib31","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1212\/WNL.0000000000004420","article-title":"High frequency of gastrointestinal manifestations in myotonic dystrophy type 1 and type 2","volume":"89","author":"Hilbert","year":"2017","journal-title":"Neurology"},{"key":"10.1016\/j.ajhg.2026.01.016_bib32","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232314779","article-title":"Clinical and Molecular Insights into Gastrointestinal Dysfunction in Myotonic Dystrophy Types 1 & 2","volume":"23","author":"Peterson","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ajhg.2026.01.016_bib33","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.cortex.2017.08.008","article-title":"The cognitive profile of myotonic dystrophy type 1: A systematic review and meta-analysis","volume":"95","author":"Okkersen","year":"2017","journal-title":"Cortex"},{"key":"10.1016\/j.ajhg.2026.01.016_bib34","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.jad.2019.03.036","article-title":"Affective symptoms and apathy in myotonic dystrophy type 1 a systematic review and meta-analysis","volume":"250","author":"van der Velden","year":"2019","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.ajhg.2026.01.016_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2023.103489","article-title":"The myotonic dystrophy type 1 drug development pipeline: 2022 edition","volume":"28","author":"Pascual-Gilabert","year":"2023","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ajhg.2026.01.016_bib36","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1089\/nat.2023.0027","article-title":"From Failure to Meet the Clinical Endpoint to U.S. Food and Drug Administration Approval: 15th Antisense Oligonucleotide Therapy Approved Qalsody (Tofersen) for Treatment of SOD1 Mutated Amyotrophic Lateral Sclerosis","volume":"33","author":"van Roon-Mom","year":"2023","journal-title":"Nucleic Acid Therapeut."},{"key":"10.1016\/j.ajhg.2026.01.016_bib37","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1093\/nar\/gkad067","article-title":"Chemistry, structure and function of approved oligonucleotide therapeutics","volume":"51","author":"Egli","year":"2023","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ajhg.2026.01.016_bib38","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1038\/nbt.3765","article-title":"The chemical evolution of oligonucleotide therapies of clinical utility","volume":"35","author":"Khvorova","year":"2017","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ajhg.2026.01.016_bib39","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1089\/nat.2014.0506","article-title":"Phosphorothioates, essential components of therapeutic oligonucleotides","volume":"24","author":"Eckstein","year":"2014","journal-title":"Nucleic Acid Therapeut."},{"key":"10.1016\/j.ajhg.2026.01.016_bib40","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232113359","article-title":"Recent Progress and Challenges in the Development of Antisense Therapies for Myotonic Dystrophy Type 1","volume":"23","author":"De Serres-B\u00e9rard","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ajhg.2026.01.016_bib41","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1177\/0192623314551840","article-title":"Antisense oligonucleotide therapies: the promise and the challenges from a toxicologic pathologist\u2019s perspective","volume":"43","author":"Frazier","year":"2015","journal-title":"Toxicol. Pathol."},{"key":"10.1016\/j.ajhg.2026.01.016_bib42","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1089\/nat.2013.0436","article-title":"Hepatotoxic potential of therapeutic oligonucleotides can be predicted from their sequence and modification pattern","volume":"23","author":"Hagedorn","year":"2013","journal-title":"Nucleic Acid Therapeut."},{"key":"10.1016\/j.ajhg.2026.01.016_bib43","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1124\/dmd.121.000418","article-title":"Adverse Drug Reactions and Toxicity of the Food and Drug Administration-Approved Antisense Oligonucleotide Drugs","volume":"50","author":"Alhamadani","year":"2022","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ajhg.2026.01.016_bib44","unstructured":"Ionis Pharmaceuticals Industry Updates On Drug Development (2018 Myotonic Dystrophy Foundation annual conference). Available online: https:\/\/www.myotonic.org\/digital-academy\/ionis-pharmaceuticals-industry-updates-drug-development-2018-mdf-annual-conference [accessed on 1 December 2022]."},{"key":"10.1016\/j.ajhg.2026.01.016_bib45","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.202013243","article-title":"Delivery of oligonucleotide-based therapeutics: challenges and opportunities","volume":"13","author":"Hammond","year":"2021","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.ajhg.2026.01.016_bib46","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1038\/s41587-022-01334-x","article-title":"Expanding RNAi therapeutics to extrahepatic tissues with lipophilic conjugates","volume":"40","author":"Brown","year":"2022","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ajhg.2026.01.016_bib47","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.addr.2015.01.008","article-title":"Pharmacokinetics, biodistribution and cell uptake of antisense oligonucleotides","volume":"87","author":"Geary","year":"2015","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ajhg.2026.01.016_bib48","doi-asserted-by":"crossref","first-page":"5901","DOI":"10.1093\/nar\/gkad415","article-title":"Targeted tissue delivery of RNA therapeutics using antibody-oligonucleotide conjugates (AOCs)","volume":"51","author":"Malecova","year":"2023","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ajhg.2026.01.016_bib49","doi-asserted-by":"crossref","first-page":"8848","DOI":"10.1021\/ja102635c","article-title":"Targeted intracellular delivery of antisense oligonucleotides via conjugation with small-molecule ligands","volume":"132","author":"Nakagawa","year":"2010","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.ajhg.2026.01.016_bib50","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1089\/nat.2020.0845","article-title":"The 10th Oligonucleotide Therapy Approved: Golodirsen for Duchenne Muscular Dystrophy","volume":"30","author":"Aartsma-Rus","year":"2020","journal-title":"Nucleic Acid Therapeut."},{"key":"10.1016\/j.ajhg.2026.01.016_bib51","first-page":"406","article-title":"Progress on RNA-based therapeutics for genetic diseases","volume":"52","author":"Luo","year":"2023","journal-title":"Zhejiang Da Xue Xue Bao Yi Xue Ban"},{"key":"10.1016\/j.ajhg.2026.01.016_bib52","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/j.omtn.2020.07.021","article-title":"Therapeutic Potential of AntagomiR-23b for Treating Myotonic Dystrophy","volume":"21","author":"Cerro-Herreros","year":"2020","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.ajhg.2026.01.016_bib53","doi-asserted-by":"crossref","DOI":"10.1088\/1758-5090\/abf6ae","article-title":"Bioengineeredin vitro3D model of myotonic dystrophy type 1 human skeletal muscle","volume":"13","author":"Fern\u00e1ndez-Garibay","year":"2021","journal-title":"Biofabrication"},{"key":"10.1016\/j.ajhg.2026.01.016_bib54","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1038\/nrd3801","article-title":"The determination and interpretation of the therapeutic index in drug development","volume":"11","author":"Muller","year":"2012","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ajhg.2026.01.016_bib55","first-page":"721","article-title":"Synthesis and Evaluation of 3\u2032-Oleyl\u2013Oligonucleotide Conjugates as Potential Cellular Uptake Enhancers","volume":"35","author":"Navarro","year":"2023","journal-title":"Synlett"},{"key":"10.1016\/j.ajhg.2026.01.016_bib56","first-page":"487","article-title":"Immortalized human myotonic dystrophy muscle cell lines to assess therapeutic compounds","volume":"10","author":"Arandel","year":"2017","journal-title":"Dis. Model. Mech."},{"key":"10.1016\/j.ajhg.2026.01.016_bib57","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1126\/science.289.5485.1769","article-title":"Myotonic dystrophy in transgenic mice expressing an expanded CUG repeat","volume":"289","author":"Mankodi","year":"2000","journal-title":"Science"},{"key":"10.1016\/j.ajhg.2026.01.016_bib58","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1093\/hmg\/9.8.1185","article-title":"Transgenic mice carrying large human genomic sequences with expanded CTG repeat mimic closely the DM CTG repeat intergenerational and somatic instability","volume":"9","author":"Seznec","year":"2000","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.ajhg.2026.01.016_bib59","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1093\/hmg\/ddw042","article-title":"A low absolute number of expanded transcripts is involved in myotonic dystrophy type 1 manifestation in muscle","volume":"25","author":"Gudde","year":"2016","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.ajhg.2026.01.016_bib60","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/978-1-4939-6817-6_22","article-title":"Ultrasensitive Hybridization-Based ELISA Method for the Determination of Phosphorodiamidate Morpholino Oligonucleotides in Biological samples","volume":"1565","author":"Burki","year":"2017","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.ajhg.2026.01.016_bib61","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.omtn.2016.11.006","article-title":"Inhibition of EGF Uptake by Nephrotoxic Antisense Drugs In Vitro and Implications for Preclinical Safety Profiling","volume":"6","author":"Moisan","year":"2017","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.ajhg.2026.01.016_bib62","doi-asserted-by":"crossref","DOI":"10.1172\/JCI185426","article-title":"The Splice Index as a prognostic biomarker of strength and function in myotonic dystrophy type 1","volume":"135","author":"Provenzano","year":"2025","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.ajhg.2026.01.016_bib63","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/978-1-0716-2010-6_13","article-title":"Rapid Determination of MBNL1 Protein Levels by Quantitative Dot Blot for the Evaluation of Antisense Oligonucleotides in Myotonic Dystrophy Myoblasts","volume":"2434","author":"Moreno","year":"2022","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.ajhg.2026.01.016_bib64","doi-asserted-by":"crossref","first-page":"3841","DOI":"10.1038\/s41467-022-31594-9","article-title":"Myotonic dystrophy RNA toxicity alters morphology, adhesion and migration of mouse and human astrocytes","volume":"13","author":"Dinc\u00e3","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ajhg.2026.01.016_bib65","first-page":"6045","article-title":"Conjugation of hydrophobic moieties enhances potency of antisense oligonucleotides in the muscle of rodents and non-human primates","volume":"47","author":"\u00d8stergaard","year":"2019","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ajhg.2026.01.016_bib66","doi-asserted-by":"crossref","first-page":"342","DOI":"10.3390\/pharmaceutics14020342","article-title":"Delivery of Oligonucleotides: Efficiency with Lipid Conjugation and Clinical Outcome","volume":"14","author":"Tran","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ajhg.2026.01.016_bib67","doi-asserted-by":"crossref","first-page":"6029","DOI":"10.1093\/nar\/gkz354","article-title":"Fatty acid conjugation enhances potency of antisense oligonucleotides in muscle","volume":"47","author":"Prakash","year":"2019","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ajhg.2026.01.016_bib68","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1021\/acs.bioconjchem.3c00085","article-title":"Propensities of Fatty Acid-Modified ASOs: Self-Assembly vs Albumin Binding","volume":"34","author":"Kusznir","year":"2023","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.ajhg.2026.01.016_bib69","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/S0022-3565(24)35315-7","article-title":"Chemically modified oligonucleotides exhibit decreased immune stimulation in mice","volume":"292","author":"Henry","year":"2000","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.ajhg.2026.01.016_bib70","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1007\/s12011-015-0339-y","article-title":"The RPTEC\/TERT1 Cell Line as an Improved Tool for In Vitro Nephrotoxicity Assessments","volume":"166","author":"Simon-Friedt","year":"2015","journal-title":"Biol. Trace Elem. Res."},{"key":"10.1016\/j.ajhg.2026.01.016_bib71","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1093\/ndt\/gfw467","article-title":"Adverse kidney effects of epidermal growth factor receptor inhibitors","volume":"32","author":"Izzedine","year":"2017","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.ajhg.2026.01.016_bib72","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1517\/14712598.2013.774366","article-title":"Influence of diverse chemical modifications on the ADME characteristics and toxicology of antisense oligonucleotides","volume":"13","author":"Dirin","year":"2013","journal-title":"Expet Opin. Biol. Ther."},{"key":"10.1016\/j.ajhg.2026.01.016_bib73","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1038\/nmeth.1267","article-title":"Detecting microRNA binding and siRNA off-target effects from expression data","volume":"5","author":"van Dongen","year":"2008","journal-title":"Nat. Methods"},{"key":"10.1016\/j.ajhg.2026.01.016_bib74","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtn.2023.09.001","article-title":"Peptide-conjugated antimiRs improve myotonic dystrophy type 1 phenotypes by promoting endogenous MBNL1 expression","volume":"34","author":"Gonz\u00e1lez-Mart\u00ednez","year":"2023","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.ajhg.2026.01.016_bib75","doi-asserted-by":"crossref","first-page":"6518","DOI":"10.1093\/nar\/gkw236","article-title":"The delivery of therapeutic oligonucleotides","volume":"44","author":"Juliano","year":"2016","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ajhg.2026.01.016_bib76","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1089\/nat.2016.0641","article-title":"Intracellular Distribution and Nuclear Activity of Antisense Oligonucleotides After Unassisted Uptake in Myoblasts and Differentiated Myotubes In Vitro","volume":"27","author":"Gonz\u00e1lez-Barriga","year":"2017","journal-title":"Nucleic Acid Therapeut."},{"key":"10.1016\/j.ajhg.2026.01.016_bib77","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.1073\/pnas.88.7.2702","article-title":"Intracellular distribution of microinjected antisense oligonucleotides","volume":"88","author":"Leonetti","year":"1991","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ajhg.2026.01.016_bib78","doi-asserted-by":"crossref","first-page":"550","DOI":"10.3390\/ijms22020550","article-title":"Loss of miR-23b\/27b\/24-1 Cluster Impairs Glucose Tolerance via Glycolysis Pathway in Mice","volume":"22","author":"Jiang","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ajhg.2026.01.016_bib79","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbr.2025.115768","article-title":"MiR-23b regulation of metabolites in neuropathic pain: A novel approach","volume":"495","author":"Hao","year":"2025","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.ajhg.2026.01.016_bib80","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1186\/s12885-019-5839-2","article-title":"miR-23b and miR-27b are oncogenic microRNAs in breast cancer: evidence from a CRISPR\/Cas9 deletion study","volume":"19","author":"Hannafon","year":"2019","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ajhg.2026.01.016_bib81","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1038\/nbt.3947","article-title":"An integrated expression atlas of miRNAs and their promoters in human and mouse","volume":"35","author":"de Rie","year":"2017","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ajhg.2026.01.016_bib82","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1161\/CIRCRESAHA.119.315856","article-title":"Preclinical and Clinical Development of Noncoding RNA Therapeutics for Cardiovascular Disease","volume":"126","author":"Huang","year":"2020","journal-title":"Circ. Res."}],"container-title":["The American Journal of Human Genetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002929726000601?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002929726000601?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T20:27:45Z","timestamp":1776716865000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002929726000601"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":82,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S0002929726000601"],"URL":"https:\/\/doi.org\/10.1016\/j.ajhg.2026.01.016","relation":{},"ISSN":["0002-9297"],"issn-type":[{"value":"0002-9297","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Enhanced muscle uptake of chemically optimized miR-23b antisense oligonucleotides as lead compounds for myotonic dystrophy type 1","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Human Genetics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajhg.2026.01.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of American Society of Human Genetics.","name":"copyright","label":"Copyright"}]}}